Common Contracts
5 similar Merger Agreement contracts by Deciphera Pharmaceuticals, Inc., Forma Therapeutics Holdings, Inc., Juniper Pharmaceuticals Inc, others
AGREEMENT AND PLAN OF MERGER by and among ONO PHARMACEUTICAL CO., LTD., TOPAZ MERGER SUB, INC. and DECIPHERA PHARMACEUTICALS, INC. Dated as of April 29, 2024Merger Agreement • April 29th, 2024 • Deciphera Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of April 29, 2024, by and among: ONO PHARMACEUTICAL CO., LTD., a Japanese company (kabushiki kaishi) (“Parent”); TOPAZ MERGER SUB, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); and DECIPHERA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 1.1.
AGREEMENT AND PLAN OF MERGER BY AND AMONG NOVO NORDISK A/S, NNUS NEW DEV, INC. and FORMA THERAPEUTICS HOLDINGS, INC. Dated as of August 31, 2022Merger Agreement • September 1st, 2022 • Forma Therapeutics Holdings, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 31, 2022, by and among: Novo Nordisk A/S, a Danish aktieselskab (“Parent”); NNUS New Dev, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Parent (“Merger Sub”); and Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 1.1.
AGREEMENT AND PLAN OF MERGER by and among Graham Holdings Company, Pacifica Merger Sub, Inc. and Leaf Group Ltd. Dated as of April 3, 2021Merger Agreement • April 5th, 2021 • Leaf Group Ltd. • Services-computer processing & data preparation • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of April 3, 2021, by and among Graham Holdings Company, a Delaware corporation (“Parent”), Pacifica Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Leaf Group Ltd., a Delaware corporation (the “Company”).
AGREEMENT AND PLAN OF MERGER by and among ROCHE HOLDINGS, INC., 022019 MERGER SUBSIDIARY, INC. and SPARK THERAPEUTICS, INC. Dated as of February 22, 2019Merger Agreement • February 25th, 2019 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of February 22, 2019, by and among: Roche Holdings, Inc., Delaware corporation (“Parent”); 022019 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); and Spark Therapeutics, Inc., a Delaware corporation (the “Company”).
AGREEMENT AND PLAN OF MERGER by and among: CATALENT PHARMA SOLUTIONS, INC., CATALENT BOSTON, INC. AND JUNIPER PHARMACEUTICALS, INC. Dated as of July 2, 2018Merger Agreement • July 3rd, 2018 • Juniper Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of July 2, 2018, by and among: CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (“Parent”); CATALENT BOSTON, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”); and JUNIPER PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
